US20190240281A1 - Oral anaerobic glutathione supplement in liposome suspension - Google Patents
Oral anaerobic glutathione supplement in liposome suspension Download PDFInfo
- Publication number
- US20190240281A1 US20190240281A1 US16/368,057 US201916368057A US2019240281A1 US 20190240281 A1 US20190240281 A1 US 20190240281A1 US 201916368057 A US201916368057 A US 201916368057A US 2019240281 A1 US2019240281 A1 US 2019240281A1
- Authority
- US
- United States
- Prior art keywords
- composition
- reduced glutathione
- essential oil
- glutathione
- user
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 title claims abstract description 248
- 108010024636 Glutathione Proteins 0.000 title claims abstract description 182
- 239000002502 liposome Substances 0.000 title abstract description 42
- 229960003180 glutathione Drugs 0.000 title description 33
- 239000013589 supplement Substances 0.000 title description 10
- 239000000725 suspension Substances 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract description 286
- 238000000034 method Methods 0.000 claims abstract description 62
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 46
- 239000002904 solvent Substances 0.000 claims abstract description 20
- 230000008809 cell oxidative stress Effects 0.000 claims abstract description 16
- 239000000341 volatile oil Substances 0.000 claims description 61
- 210000002966 serum Anatomy 0.000 claims description 34
- 235000005979 Citrus limon Nutrition 0.000 claims description 22
- 244000131522 Citrus pyriformis Species 0.000 claims description 22
- 235000010241 potassium sorbate Nutrition 0.000 claims description 21
- 239000004302 potassium sorbate Substances 0.000 claims description 21
- 235000010234 sodium benzoate Nutrition 0.000 claims description 21
- 239000004299 sodium benzoate Substances 0.000 claims description 21
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 20
- 244000246386 Mentha pulegium Species 0.000 claims description 20
- 235000016257 Mentha pulegium Nutrition 0.000 claims description 20
- 235000004357 Mentha x piperita Nutrition 0.000 claims description 20
- 235000001050 hortel pimenta Nutrition 0.000 claims description 20
- 229940069338 potassium sorbate Drugs 0.000 claims description 20
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 claims description 20
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 claims description 18
- 239000007788 liquid Substances 0.000 claims description 11
- 238000011282 treatment Methods 0.000 claims description 11
- 239000000843 powder Substances 0.000 claims description 9
- 235000013399 edible fruits Nutrition 0.000 claims description 8
- 239000000796 flavoring agent Substances 0.000 claims description 8
- 235000019634 flavors Nutrition 0.000 claims description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 6
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 6
- 238000001990 intravenous administration Methods 0.000 claims description 6
- 238000007918 intramuscular administration Methods 0.000 claims description 5
- 239000003755 preservative agent Substances 0.000 claims description 5
- 230000000699 topical effect Effects 0.000 claims description 5
- 241000675108 Citrus tangerina Species 0.000 claims description 4
- 240000001238 Gaultheria procumbens Species 0.000 claims description 4
- 235000007297 Gaultheria procumbens Nutrition 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 4
- 244000178870 Lavandula angustifolia Species 0.000 claims description 4
- 235000010663 Lavandula angustifolia Nutrition 0.000 claims description 4
- 244000024873 Mentha crispa Species 0.000 claims description 4
- 235000014749 Mentha crispa Nutrition 0.000 claims description 4
- 241001409321 Siraitia grosvenorii Species 0.000 claims description 4
- 229930006000 Sucrose Natural products 0.000 claims description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 4
- 239000012141 concentrate Substances 0.000 claims description 4
- 239000008103 glucose Substances 0.000 claims description 4
- 235000012907 honey Nutrition 0.000 claims description 4
- 239000001102 lavandula vera Substances 0.000 claims description 4
- 235000018219 lavender Nutrition 0.000 claims description 4
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 claims description 4
- 229960004793 sucrose Drugs 0.000 claims description 4
- 239000005711 Benzoic acid Substances 0.000 claims description 3
- 235000010233 benzoic acid Nutrition 0.000 claims description 3
- 238000011866 long-term treatment Methods 0.000 claims description 2
- 238000011200 topical administration Methods 0.000 claims description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims 4
- CIWBSHSKHKDKBQ-DUZGATOHSA-N D-araboascorbic acid Natural products OC[C@@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-DUZGATOHSA-N 0.000 claims 2
- 244000228451 Stevia rebaudiana Species 0.000 claims 2
- 244000193174 agave Species 0.000 claims 2
- 229960004365 benzoic acid Drugs 0.000 claims 2
- 235000010350 erythorbic acid Nutrition 0.000 claims 2
- 239000004318 erythorbic acid Substances 0.000 claims 2
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 claims 2
- 239000004222 ferrous gluconate Substances 0.000 claims 2
- 229960001645 ferrous gluconate Drugs 0.000 claims 2
- 235000013924 ferrous gluconate Nutrition 0.000 claims 2
- VRIVJOXICYMTAG-IYEMJOQQSA-L iron(ii) gluconate Chemical compound [Fe+2].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O VRIVJOXICYMTAG-IYEMJOQQSA-L 0.000 claims 2
- 229940026239 isoascorbic acid Drugs 0.000 claims 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 claims 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 claims 2
- 229960002216 methylparaben Drugs 0.000 claims 2
- WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 claims 2
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims 2
- 235000010235 potassium benzoate Nutrition 0.000 claims 2
- 239000004300 potassium benzoate Substances 0.000 claims 2
- 229940103091 potassium benzoate Drugs 0.000 claims 2
- 229940092258 rosemary extract Drugs 0.000 claims 2
- 235000020748 rosemary extract Nutrition 0.000 claims 2
- 239000001233 rosmarinus officinalis l. extract Substances 0.000 claims 2
- 229960003885 sodium benzoate Drugs 0.000 claims 2
- 239000001509 sodium citrate Substances 0.000 claims 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims 2
- 229960001790 sodium citrate Drugs 0.000 claims 2
- 235000011083 sodium citrates Nutrition 0.000 claims 2
- 235000010352 sodium erythorbate Nutrition 0.000 claims 2
- 239000004320 sodium erythorbate Substances 0.000 claims 2
- RBWSWDPRDBEWCR-RKJRWTFHSA-N sodium;(2r)-2-[(2r)-3,4-dihydroxy-5-oxo-2h-furan-2-yl]-2-hydroxyethanolate Chemical compound [Na+].[O-]C[C@@H](O)[C@H]1OC(=O)C(O)=C1O RBWSWDPRDBEWCR-RKJRWTFHSA-N 0.000 claims 2
- 235000010199 sorbic acid Nutrition 0.000 claims 2
- 239000004334 sorbic acid Substances 0.000 claims 2
- 229940075582 sorbic acid Drugs 0.000 claims 2
- 230000036542 oxidative stress Effects 0.000 abstract description 33
- 108010053070 Glutathione Disulfide Proteins 0.000 description 56
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 56
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 45
- 238000004458 analytical method Methods 0.000 description 24
- 230000007774 longterm Effects 0.000 description 20
- 241000544066 Stevia Species 0.000 description 16
- 150000003254 radicals Chemical class 0.000 description 16
- 229940005741 sunflower lecithin Drugs 0.000 description 16
- 230000002829 reductive effect Effects 0.000 description 14
- 230000037406 food intake Effects 0.000 description 13
- 241000196324 Embryophyta Species 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 10
- 238000004519 manufacturing process Methods 0.000 description 10
- 239000001301 oxygen Substances 0.000 description 10
- 229910052760 oxygen Inorganic materials 0.000 description 10
- PWKSKIMOESPYIA-BYPYZUCNSA-N L-N-acetyl-Cysteine Chemical compound CC(=O)N[C@@H](CS)C(O)=O PWKSKIMOESPYIA-BYPYZUCNSA-N 0.000 description 9
- 230000008901 benefit Effects 0.000 description 9
- 238000007254 oxidation reaction Methods 0.000 description 9
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 210000004369 blood Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 7
- 230000003647 oxidation Effects 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 238000012384 transportation and delivery Methods 0.000 description 7
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 6
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 6
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 6
- 235000018417 cysteine Nutrition 0.000 description 6
- 239000012895 dilution Substances 0.000 description 6
- 238000010790 dilution Methods 0.000 description 6
- 239000000787 lecithin Substances 0.000 description 6
- 229940067606 lecithin Drugs 0.000 description 6
- 235000010445 lecithin Nutrition 0.000 description 6
- 230000001590 oxidative effect Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 238000001784 detoxification Methods 0.000 description 5
- 229910052717 sulfur Inorganic materials 0.000 description 5
- 239000011593 sulfur Substances 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 239000004471 Glycine Substances 0.000 description 4
- 239000000232 Lipid Bilayer Substances 0.000 description 4
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 4
- 239000003963 antioxidant agent Substances 0.000 description 4
- 235000006708 antioxidants Nutrition 0.000 description 4
- 238000003556 assay Methods 0.000 description 4
- 230000001413 cellular effect Effects 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 210000004185 liver Anatomy 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 150000003904 phospholipids Chemical class 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000005855 radiation Effects 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 241000208818 Helianthus Species 0.000 description 3
- 235000003222 Helianthus annuus Nutrition 0.000 description 3
- 101150053185 P450 gene Proteins 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 229910001385 heavy metal Inorganic materials 0.000 description 3
- 230000002209 hydrophobic effect Effects 0.000 description 3
- 230000000968 intestinal effect Effects 0.000 description 3
- 238000002483 medication Methods 0.000 description 3
- 231100000783 metal toxicity Toxicity 0.000 description 3
- 230000037125 natural defense Effects 0.000 description 3
- 229960005489 paracetamol Drugs 0.000 description 3
- 150000002978 peroxides Chemical class 0.000 description 3
- 125000003396 thiol group Chemical group [H]S* 0.000 description 3
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 2
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 2
- 240000004246 Agave americana Species 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 2
- XJLXINKUBYWONI-NNYOXOHSSA-N NADP zwitterion Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-NNYOXOHSSA-N 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 230000002009 allergenic effect Effects 0.000 description 2
- 235000001014 amino acid Nutrition 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 229940072107 ascorbate Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229960003067 cystine Drugs 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 235000019197 fats Nutrition 0.000 description 2
- 235000019249 food preservative Nutrition 0.000 description 2
- 239000005452 food preservative Substances 0.000 description 2
- 229940045883 glutathione disulfide Drugs 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 230000003284 homeostatic effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000003093 intracellular space Anatomy 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000004064 recycling Methods 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 2
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- UUFQTNFCRMXOAE-UHFFFAOYSA-N 1-methylmethylene Chemical compound C[CH] UUFQTNFCRMXOAE-UHFFFAOYSA-N 0.000 description 1
- PWKSKIMOESPYIA-UHFFFAOYSA-N 2-acetamido-3-sulfanylpropanoic acid Chemical compound CC(=O)NC(CS)C(O)=O PWKSKIMOESPYIA-UHFFFAOYSA-N 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 description 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 description 1
- 206010003805 Autism Diseases 0.000 description 1
- 208000020706 Autistic disease Diseases 0.000 description 1
- 206010008874 Chronic Fatigue Syndrome Diseases 0.000 description 1
- 206010009866 Cold sweat Diseases 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 1
- 238000009017 Fluorometric Assay Kit Methods 0.000 description 1
- 208000001914 Fragile X syndrome Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 108010063907 Glutathione Reductase Proteins 0.000 description 1
- 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 description 1
- 102100034294 Glutathione synthetase Human genes 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 208000000616 Hemoptysis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- RWSXRVCMGQZWBV-PHDIDXHHSA-N L-Glutathione Natural products OC(=O)[C@H](N)CCC(=O)N[C@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-PHDIDXHHSA-N 0.000 description 1
- 229930182816 L-glutamine Natural products 0.000 description 1
- 208000005870 Lafora disease Diseases 0.000 description 1
- 208000014161 Lafora myoclonic epilepsy Diseases 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- 208000002720 Malnutrition Diseases 0.000 description 1
- 102000003792 Metallothionein Human genes 0.000 description 1
- 108090000157 Metallothionein Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 208000003286 Protein-Energy Malnutrition Diseases 0.000 description 1
- 208000036071 Rhinorrhea Diseases 0.000 description 1
- 206010039101 Rhinorrhoea Diseases 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 102000002933 Thioredoxin Human genes 0.000 description 1
- 206010047642 Vitiligo Diseases 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 229960004308 acetylcysteine Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 229940087168 alpha tocopherol Drugs 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 230000006851 antioxidant defense Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 210000000695 crystalline len Anatomy 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000006392 deoxygenation reaction Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 229910001882 dioxygen Inorganic materials 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 229940011871 estrogen Drugs 0.000 description 1
- 239000000262 estrogen Substances 0.000 description 1
- 210000001723 extracellular space Anatomy 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000001408 fungistatic effect Effects 0.000 description 1
- 108010068906 gamma-glutamylcysteine Proteins 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 210000000738 kidney tubule Anatomy 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- 239000012263 liquid product Substances 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000029766 myalgic encephalomeyelitis/chronic fatigue syndrome Diseases 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000004783 oxidative metabolism Effects 0.000 description 1
- 150000002926 oxygen Chemical class 0.000 description 1
- -1 oxygen radical Chemical class 0.000 description 1
- 210000004738 parenchymal cell Anatomy 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 150000003905 phosphatidylinositols Chemical class 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 235000020826 protein-energy malnutrition Nutrition 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 239000012048 reactive intermediate Substances 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000010282 redox signaling Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 208000007056 sickle cell anemia Diseases 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 108060008226 thioredoxin Proteins 0.000 description 1
- 229960000984 tocofersolan Drugs 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000002676 xenobiotic agent Substances 0.000 description 1
- 239000002076 α-tocopherol Substances 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
- RITKHVBHSGLULN-CRCLSJGQSA-N γ-glutamylcysteine Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](CS)C(O)=O RITKHVBHSGLULN-CRCLSJGQSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
- A61K38/063—Glutathione
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1833—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule
- A61K49/1839—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule the small organic molecule being a lipid, a fatty acid having 8 or more carbon atoms in the main chain, or a phospholipid
Definitions
- compositions, methods, and systems that are efficient for reducing free radical levels in a user and alleviating oxidative stress in the user.
- the disclosure provides such compositions, methods, and systems that can treat oxidative stress and improving the body's natural detoxification process and natural defense systems in an effective and elegant manner.
- FIG. 1 illustrates the chemical structure of reduced glutathione (GSH) according to one implementation consistent with the teachings and principles of the disclosure
- FIG. 2 illustrates the chemical oxidation reaction of reduced glutathione (GSH) to oxidized glutathione (GSSG) according to one implementation consistent with the teachings and principles of the disclosure;
- FIG. 3 illustrates a standard curve for reduced glutathione resulting from a short-term analysis of a clinical example consistent with the teachings and principles of the disclosure
- FIG. 4 illustrates a standard curve for reduced glutathione resulting from a long-term analysis of a clinical example consistent with the teachings and principles of the disclosure
- FIG. 5 illustrates concentrations of reduced glutathione resulting from a short-term analysis of a clinical example consistent with the teachings and principles of the disclosure
- FIG. 6 illustrates concentrations of oxidized glutathione resulting from a short-term analysis of a clinical example consistent with the teachings and principles of the disclosure
- FIG. 7 illustrates ratios of reduced glutathione to oxidized glutathione resulting from a short-term analysis of a clinical example consistent with the teachings and principles of the disclosure
- FIG. 8 illustrates concentrations of reduced glutathione resulting from a long-term analysis of a clinical example consistent with the teachings and principles of the disclosure
- FIG. 10 illustrates ratios of reduced glutathione to oxidized glutathione resulting from a long-term analysis of a clinical example consistent with the teachings and principles of the disclosure
- the disclosure extends to compositions, methods, and systems for alleviating oxidative stress in a user and/or the reducing the levels of damaging free radicals in the user that may be accumulated due to viruses, bacteria, heavy metal toxicity, radiation, certain medications, the process of aging, and the like.
- the disclosure further extends to the anaerobic manufacture, packaging, and delivery of therapeutic amounts of bio-effective reduced glutathione (GSH).
- GSH bio-effective reduced glutathione
- compositions known in the art that purport to provide reduced glutathione Compared with compositions known in the art that purport to provide reduced glutathione, the composition of the present disclosure provides unexpectedly good results in preventing the oxidation of reduced glutathione (GSH) to oxidized glutathione (GSSG) that is commonly found in purported GSH supplements known in the art.
- the composition provides unexpectedly good results in passing reduced glutathione through the mucosa membrane of a user directly into the user's bloodstream such that the user may receive effective relief from cellular oxidative stress and may reduce the levels of free radicals in the body.
- the composition of the disclosure provides unexpectedly good results in increasing levels of reduced glutathione in a user's blood serum over short-term and long-term periods.
- the composition further provides unexpectedly good results in improving the ratio of reduced glutathione to oxidized glutathione in a user's blood serum over short-term and long-term periods.
- the disclosure further extends to the anaerobic manufacture and packaging of a composition for reducing oxidative stress in a user.
- the composition provides reduced glutathione in a deoxygenated water solvent, wherein all or nearly all oxygen gas (O 2 ) commonly found in water has been removed.
- the composition is encapsulated in a phospholipid liposome structure that provides some protection against oxidation of the reduced glutathione.
- the composition is further packaged in an airless dispenser.
- the composition provides high bio-activity in alleviating cellular oxidative stress in a user and reducing levels of free radicals in a user's body.
- an effective amount means an amount of an ingredient or a component of the product that is nontoxic, but sufficient to provide the desired effect and performance at a reasonable benefit/risk ratio attending any dietary supplement or product.
- an effective amount of a vitamin or mineral is an amount sufficient to prevent a deficiency thereof and to reduce the incidence of some adverse effects.
- oxidative stress is thought to be involved in the development of attention deficit hyperactivity disorder, cancer, Parkinson's disease, Lafora disease, Alzheimer's disease, atherosclerosis, heart failure, myocardial infarction, fragile X syndrome, sickle-cell disease, licen planus, vitiligo, autism, infection, chronic fatigue syndrome, and depression, among other.
- oxidative stress is associated with increased production of oxidizing species or a significant decrease in the effectiveness of antioxidant defenses, such as glutathione.
- Reduced glutathione (GSH) is often referred to as the body's master antioxidant.
- Glutathione is composed of three amino acids, including cysteine, glycine, and glutamine, and glutathione can be found in virtually every cell of the body. The highest concentration of glutathione is typically found in the liver where it serves a critical function in the body's natural detoxification process. This natural detoxification process is important for treating oxidative stress in the body and avoiding the production of damaging peroxides and free radicals.
- Glutathione is an important component of the body's natural defense system. Glutathione can be depleted by compositions or processes that are associated with free-radical damage, including for example, viruses, bacteria, heavy metal toxicity, radiation, certain medications, and the process of aging. The depletion of glutathione is associated with lower immune function, increased vulnerability to infection, and a reduction in the liver's ability to detoxify the body. As the generation of free radicals exceeds the body's ability to neutralize and eliminate them, oxidative stress occurs. A primary function of glutathione is to alleviate oxidative stress.
- Reduced glutathione is under tight homeostatic control both intracellularly and extracellularly. A dynamic balance is maintained between the synthesis of reduced glutathione, its recycling from oxidized glutathione, and its utilization.
- Reduced glutathione is utilized as a cofactor by multiple peroxidase enzymes to detoxify peroxides that are generated by oxygen radical attack on biological molecules.
- Reduced glutathione is further utilized as a cofactor by transhydrogenases to reduce oxidized centers on DNA, proteins, and other biomolecules.
- Reduced glutathione is further utilized as a cofactor by glutathione S-transferases (hereinafter “GST”) to conjugate reduced glutathione with endogenous substances (e.g. estrogens), exogenous electrophiles (e.g. arene oxides, unsaturated carbonyls, and organic halides), and diverse xenobiotics.
- endogenous substances e.g. estrogens
- exogenous electrophiles e.g. arene oxides, unsaturated carbonyls, and organic halides
- diverse xenobiotics e.g. arene oxides, unsaturated carbonyls, and organic hal
- cystine i.e., the oxidized and more stable form of cysteine.
- Cells import cystine from the blood, reconvert it to cysteine, and form it to synthesize reduced glutathione.
- reduced glutathione assists in re-reducing oxidized forms of other antioxidants such as ascorbate and alpha-tocopherol.
- Reduced glutathione is an important cell protectant; it directly quenches reactive hydroxyl free radicals, other oxygen-centered free radicals, and radical centers on DNA and other biomolecules.
- Reduced glutathione is a primary protectant of the skin, lens, cornea, and retina against radiation damage and other biochemical foundations of P450 detoxification in the liver, kidneys, lungs, intestinal, epithelia, and other organs.
- a method of reducing oxidative stress in a user includes providing a composition to the user, wherein the composition comprises an effective amount of reduced glutathione for reducing oxidative stress in the user and a deoxygenated water solvent.
- the composition is encapsulated in a phospholipid liposome structure and the composition is packaged in an airless dispenser configured to maintain an anaerobic environment.
- a method for manufacturing a composition for reducing oxidative stress in a user includes mixing reduced glutathione powder and deoxygenated water in an anaerobic environment to form a reduced glutathione solution.
- the method includes packaging the reduced glutathione solution in an airless dispenser in an anaerobic environment such that the reduced glutathione is not substantially exposed to an oxygen source from manufacture to dispensing.
- the composition is encapsulated in a liposome structure.
- the liposome structure may be a spherical lipid-based vesicle constructed from sunflower-based lecithin rich in plant-based phospholipids.
- the liposome structure may have a hollow core including an aqueous solution of the reduced glutathione in deoxygenated water with other components as disclosed herein.
- the liposome structure may provide enhanced and targeted delivery to a user through the user's oral, esophageal, and gastrointestinal mucosa lining.
- the liposome structure may comprise any suitable liposome structure and is not limited to a spherical lipid-based vesicle from sunflower-based lecithin.
- Sunflower-based lecithin has a low affinity for allergenic response as compared to soy lecithin and may be advantageous for certain users who are disposed to allergenic reactions.
- the phospholipids in the lecithin are responsible for organized formation of a liposome vesicle by providing lipid molecules, especially phosphatidylcholine, containing a hydrophilic head and hydrophobic tail, that has a binding capacity to form a spherical vesicle including at least one lipid bilayer.
- the hydrophilic head is located on an outer shell and the hydrophobic tail is oriented toward an inner surface of the vesicle shell.
- a liposome has an aqueous solution core surrounded by a hydrophobic membrane in the form of a lipid bilayer. Hydrophilic solutes, such as reduced glutathione, are dissolved in the core and cannot readily pass through the lipid bilayer.
- the lipid bilayer may fuse with other bilayers, such as a cell wall, and deliver the liposome contents.
- the liposomes comprise more than l0 wt % the total composition.
- An increased liposomal population may maximize the encapsulation of the deoxygenated aqueous reduced glutathione and solute to a theoretical efficiency of about 50% of the aqueous medium.
- liposomes of the composition primarily perform the function of targeted delivery and slow release of the deoxygenated aqueous reduced glutathione. Further, some oxidative protection is afforded by the liposome vesicle in the form of an oxygen permeability rate limited reducing oxidation of the internal contents after dispensing the composition.
- the consumer liquid product package which in an embodiment includes an airless dispenser, eventually all components of the composition will reach a similar oxygen saturation and level.
- FIG. 1 illustrates the chemical structure 100 of reduced glutathione.
- reduced glutathione comprises glutamic acid 102, cysteine 104, and glycine 106.
- Reduced glutathione is a linear tripeptide of L-glutamine, L-cysteine, and glycine.
- Reduced glutathione is technically referred to as N-L-gamma-glutamyl-cysteinyl glycine or L-glutathione.
- the molecule includes a sulfhydryl (SH) group on the cysteinyl portion that accounts for its strong electron-donating character that enables glutathione to be effective in reducing oxidative stress in the body.
- SH sulfhydryl
- the synthesis of reduced glutathione includes two closely linked and enzymatically-controlled reactions that utilize adenosine triphosphate (ATP).
- ATP adenosine triphosphate
- cysteine and glutamate are combined by gamma-glutamyl cysteinyl synthetase.
- reduced glutathione synthetase combines gamma-glutamylcysteine with glycine to generate reduced glutathione.
- cysteine availability is usually rate-limiting. Fasting, protein-energy malnutrition, and other dietary amino acid deficiencies limit the synthesis of reduced glutathione.
- glutathione disulfide reductase which uses reducing equivalents from nicotinamide adenine dinucleotide phosphate (NADPH) to reconvert oxidized glutathione to glutathione disulfide.
- NADPH nicotinamide adenine dinucleotide phosphate
- the reducing power of ascorbate helps conserve systemic reduced glutathione.
- FIG. 2 illustrates the oxidation reaction 204 of reduced glutathione (GSH) 202 to oxidized glutathione (GSSG) 208 .
- the reaction 204 produces two electrons and two protons as illustrated at 206 .
- a composition is provided to a user.
- the composition includes 99.9% purity reduced glutathione powder.
- the reduced glutathione powder is solubilized in a deoxygenated water solvent and encapsulated in a plant-based phospholipid liposome structure.
- the composition includes an effective amount of stevia , natural lemon essential oil, and natural peppermint essential for improving the overall flavor of the composition for human oral consumption.
- the composition includes from about 525 mg to about 575 mg of reduced glutathione per 4 g of solution.
- the resulting liquid composition is packaged in an airless dispenser that is configured to maintain the composition in an anaerobic environment.
- the airless dispenser protects the reduced glutathione from degradation and conversion to oxidized glutathione.
- Previous purported supplements including reduced glutathione suffer from a sulfur smell due to the strong oxidation of reduced glutathione.
- the airless dispenser extends the effective shelf-life of the reduced glutathione in the present disclosure by substantially eliminating contact of the reduced glutathione with oxygen, even after first use of the composition.
- Applicant recognizes that other forms of packaging and delivery result in the reduced glutathione making contact with oxygen and thus rapidly degrading and oxidizing into oxidized glutathione, even if a successful manufacture of reduced glutathione is initially achieved.
- the participants After the collection of the baseline serum sample, the participants immediately consumed the composition by dispensing 4 mL of the liquid composition into their mouth and swishing for 15-20 seconds before swallowing. The participants refrained from drinking for 15 minutes afterward. The participant who used the product topically applied approximately the same amount of the composition onto the abdomen and soft areas under the arms. Samples of the participants' blood were against collected at 2 hours, 6 hours, and 8 hours after the first collection. The participants consumed the composition one time per day in the morning for a four-week period. The participants' blood was collected each week at exactly seven-day intervals for four weeks at approximately 10:00 AM. The participants were instructed to consume the composition four hours prior to collection. The serum was extracted, processed, and frozen for later analysis. All serum samples were assayed within thirty days of collection.
- the serum samples were analyzed to determine the levels of reduced glutathione and oxidized glutathione.
- the serum samples were analyzed using the BioVision (Milpitas, Calif.) Glutathione Fluorometric Assay Kit (GSH, GSSG, and Total) k264. Wasatch Scientific Laboratories in Murray, Utah, USA was contracted to perform the assay using the BioVision fluorometric kit and method.
- Whole blood samples were collected and immediately centrifuged to separate the serum from the red blood cells and heavier components. Approximately 120 ⁇ L of serum was added to 40 ⁇ L of an ice-cold perchloric acid PCA buffer in a 1 mL aliquot. The solution was vortexed and stored on ice for five minutes. The solution was centrifuged at 13,000 G for two minutes, and the supernatant was collected and frozen at ⁇ 60 degC.
- FIG. 3 illustrates a standard curve for reduced glutathione for the short-term analysis.
- the standard curve for reduced glutathione and oxidized glutathione were created, and then the prepared serum samples were tested at two dilutions to determine the optimal dilution for the best dynamic resolution of the assay.
- the samples were processed and assayed in duplicate pairs at the chosen dilution. The results of each pair were reviewed and compared for repeatability and best-fit samples were used.
- FIG. 3 illustrates a mass of reduced glutathione (GSH) in nanograms on the x-axis plotted against the relative fluorescence units (RFU) on the y-axis.
- GSH reduced glutathione
- FIG. 5 illustrates concentrations of reduced glutathione for each of the four aforementioned participants for the short-term analysis.
- FIG. 5 illustrates concentrations in ⁇ g/mL for each of four possible serum draws for each of the four participants.
- Draw one is the baseline draw.
- Draw two was taken at the baseline plus four hours.
- Draw three was taken at the baseline plus six hours.
- Draw four was taken at the baseline plus eight hours.
- all participants in the short-term analysis experienced an increase in serum levels of reduced glutathione.
- the increase concentration of reduced glutathione appeared to peak at approximately six to eight hours after ingestion.
- the increase in reduced glutathione was on average 30% above baseline levels. Participant one, a female, applied the composition topically and experienced elevated serum levels of reduced glutathione.
- FIG. 7 illustrates the ratios of reduced glutathione to oxidized glutathione for each of the participants for the short-term analysis.
- the composition provided a short-term antioxidant benefit to each of the participants.
- the reduced/oxidized glutathione ratio is an accepted standard to measure cellular oxidative stress.
- This study illustrates the redox ratio trend over time. After ingestion, each participant experienced an increase in the redox ratio compared to the baseline, even eight hours after consuming or applying the composition. This study demonstrates bio-utilization of the redox ratio.
- FIG. 8 illustrates concentrations of reduced glutathione for each of the four aforementioned participants for the long-term analysis.
- FIG. 8 illustrates concentrations in ⁇ g/mL for each of three weekly serum draws for each of the four participants.
- Draw one (not shown due to laboratory error) was taken at 10:00 AM exactly one week after ingestion or application of the composition.
- Draw two occurred at 10:00 AM two weeks after ingestion or application of the composition.
- Draw three occurred at 10:00 AM exactly three weeks after ingestion or application of the composition.
- Draw four occurred at 10:00 AM exactly four weeks after ingestion or application of the composition.
- the human serum samples were assayed for concentrations of reduced and oxidized glutathione.
- Participant one, a female applied the composition topically and participants two, three, and four ingested orally a liquid-based composition.
- the participants' serum levels of reduced glutathione show mixed results. Participants one and three demonstrates levels of reduced glutathione that are very close to the baseline levels without significant increase. Participants two and four demonstrated long-term increase in levels of reduced glutathione equal to approximately 20-22%. The long-term serum levels of reduced glutathione when viewed alone showed positive results in participants two and four.
- FIG. 9 illustrates concentrations of oxidized glutathione for each of the four aforementioned participants for the long-term analysis.
- FIG. 9 illustrates concentrations in ⁇ g/mL for each of three weekly serum draws for each of the four participants.
- Draw one (not shown due to laboratory error) was taken at 10:00 AM exactly one week after ingestion or application of the composition.
- Draw two occurred at 10:00 AM two weeks after ingestion or application of the composition.
- Draw three occurred at 10:00 AM exactly three weeks after ingestion or application of the composition.
- Draw four occurred at 10:00 AM exactly four weeks after ingestion or application of the composition.
- the human serum samples were assayed for concentrations of reduced and oxidized glutathione.
- Participant one, a female applied the composition topically and participants two, three, and four ingested orally a liquid-based composition.
- oxidized glutathione As illustrated in FIG. 9 , each of the four participants experienced a significant decrease in long-term concentrations of oxidized glutathione (GSSG). As discussed previously, reduced glutathione is oxidized inside cells and converted to oxidized glutathione according to the reaction 200 illustrated in FIG. 2 . A portion of the oxidized glutathione is shuttled out of the cells and into the intracellular space and into the blood. When the ratio of reduced/oxidized glutathione is calculated, a true reduction is cellular oxidation is evidence.
- FIG. 10 illustrates the ratios of reduced glutathione to oxidized glutathione for each of the four aforementioned participants for the long-term analysis.
- each of the participants experienced a sustained and cumulative decrease in oxidative stress.
- the reduced/oxidized glutathione redox ratio increased for all participants over the four weeks of ingesting or applying the composition.
- Applicant notes that participant three and participant four represent a wide age and health gap, where one is a 23-year-old healthy female and the other is an 83-year old female with health issues due to age.
- the composition had a positive long-term effect in both the young participant and the older participant, where the older participant experienced a greater rise in the redox ratio.
- the effects of the novel composition comprising reduced glutathione that is disclosed herein indicate a bioavailability of reduced glutathione and its short-term and long-term benefits in the human body as indicated in the serum concentrations of reduced glutathione (GSH) and oxidized glutathione (GSSG). All participants experienced a noticeable increase in GSH/GSSG redox ratio indicating a true reduction in cellular oxidative stress, with the older participants (age 55-83) experiencing higher ratios. This is consistent with the assumption that older participants have a greater amount of cellular oxidative stress to be reduced.
- the results of the clinical example demonstrate conclusively that the composition disclosed herein is effectively delivering reduced glutathione.
- the composition includes reduced glutathione and a deoxygenated water solvent.
- the composition is manufactured and packaged in an anaerobic environment, in stark contrast with previous supplements known in the art that purport to deliver reduced glutathione but instead deliver oxidized glutathione.
- the careful maintenance of an anaerobic condition, as disclosed herein provides the unexpected result (given all prior failures) of a composition that genuinely comprises reduced glutathione.
- the composition disclosed herein provides increased levels of reduced glutathione, reduced cellular oxidative stress, and provides all the appurtenant benefits.
- the composition is provided for the treatment of acetaminophen overdose.
- the molecule known as N-acetylcysteine (hereinafter “NAC”) is known in the art for the treatment of acetaminophen overdose.
- NAC N-acetylcysteine
- Pharmaceutical NAC is primarily used in medical settings for respiratory conditions, to manage acetaminophen overdose, and to prevent radio-contrast-induced nephropathy. However, the half-life of NAC is approximately 5.6 hours, and 30% of NAC is renally excreted by the body. Orally administered or inhaled NAC is associated with drowsiness, stomatitis, clamminess, rhinorrhea, and hemoptysis, and NAC is a category B pregnancy risk.
- the shelf-life of the composition disclosed herein is at least one year. Therefore, the composition disclosed herein provides an alternative to NAC that is shelf-stable for an extended period and demonstrates high viability and efficacy.
- the composition includes highly pure L-glutathione reduced.
- the reduced glutathione comprises a purity from about 98% to about 99.9% purity.
- the purity is from about 90% to about 99.9% purity.
- the purity is from about 95% to about 99.9% purity.
- the purity is from about 99.0% to about 99.9% purity. It should be appreciated that various ranges of purity may be extracted from any of the aforementioned ranges as if those ranges were disclosed explicitly.
- the composition includes lemon essential oil.
- Lemon essential oil may be provided to improve an overall flavor of the composition.
- oxidized glutathione provides a sulfur smell that may be pungent or off-putting to a user.
- the composition of the present disclosure may oxidize with oxygen in the air when the composition is being ingested, and the oxidized may cause the composition to become unpalatable to the user immediately before the user ingests the composition.
- the lemon essential oil may be provided to counteract the sulfur smell of the oxidized glutathione and increase the flavor of the composition.
- the composition includes stevia extract.
- the stevia extract may be provided to improve the overall flavor of the composition and mask a sulfur smell arising from the oxidation of the reduced glutathione.
- the composition includes potassium sorbate.
- Potassium sorbate is a known food preservative and has an E number of E202.
- Potassium sorbate is known for inhibiting molds and yeasts in a variety of foods and liquids.
- Potassium sorbate is included in the composition as a preservative in an embodiment of the disclosure.
- Chart 2 shows an example embodiment of the composition.
- Components were dissolved in deoxygenated water and encapsulated in a plant-based phospholipid liposome structure.
- the composition was packaged and stored in an airless dispenser.
- Chart 3 shows an example embodiment of the composition.
- Components were dissolved in deoxygenated water and encapsulated in a plant-based phospholipid liposome structure.
- the composition was packaged and stored in an airless dispenser.
- Chart 4 shows an example embodiment of the composition.
- Components were dissolved in deoxygenated water and encapsulated in a plant-based phospholipid liposome structure.
- the composition was packaged and stored in an airless dispenser.
- Chart 5 below shows an example embodiment of the composition.
- Components were dissolved in deoxygenated water and encapsulated in a plant-based phospholipid liposome structure.
- the composition was packaged and stored in an airless dispenser.
- Chart 7 below shows an example embodiment of the composition.
- Components were dissolved in deoxygenated water and encapsulated in a plant-based phospholipid liposome structure.
- the composition was packaged and stored in an airless dispenser.
- Example 2 is a composition as in Example 1, wherein the composition is encapsulated in a phospholipid liposome structure.
- Example 4 is a composition as in any of Examples 1-3, wherein the reduced glutathione comprises from about 8% to about 14% by weight of the total composition.
- Example 5 is a composition as in any of Examples 1-4, wherein the composition comprises from about 500 mg to about 600 mg reduced glutathione per 4 g of the composition.
- Example 8 is a composition as in any of Examples 1-7, further comprising an effective amount of potassium sorbate for preserving the composition.
- Example 11 is a composition as in any of Examples 1-10, wherein the composition is prepared for topical application.
- Example 13 is a composition as in any of Examples 1-12, wherein the reduced glutathione comprises from about 4 g to about 20 g per 100 mL of the deoxygenated water solvent.
- Example 15 is a method as in Example 14, wherein the composition is encapsulated in a phospholipid liposome structure.
- Example 16 is a method as in any of Example 14-15, wherein the composition is packaged in an airless dispenser configured to maintain an anaerobic environment.
- Example 17 is a method as in any of Example 14-16, wherein the reduced glutathione comprises from about 8% to about 14% by weight of the total composition.
- Example 18 is a method as in any of Example 14-17, wherein the composition comprises from about 500 mg to about 600 mg reduced glutathione per 4 g of the composition.
- Example 20 is a method as in any of Example 14-19, wherein the reduced glutathione comprises a purity from about 99.0% to about 99.9% purity.
- Example 22 is a method as in any of Example 14-21, wherein the composition further comprises an effective amount of potassium sorbate for preserving the composition.
- Example 24 is a method as in any of Example 14-23, wherein the composition is provided to the user for liquid oral consumption.
- Example 25 is a method as in any of Example 14-24, wherein the composition is provided to the user for topical administration.
- Example 26 is a method as in any of Example 14-25, wherein the composition is provided to the user for intravenous or intramuscular administration.
- Example 27 is a method as in any of Example 14-26, wherein the reduced glutathione comprises from about 4 g to about 20 g per 100 mL of the deoxygenated water solvent.
- Example 28 is a method as in any of Example 14-27, wherein the composition is provided to the user for short-term treatment of cellular oxidative stress.
- Example 29 is a method as in any of Example 14-28, wherein the composition increases blood-serum levels of reduced glutathione in the user by at least 25%.
- Example 30 is a method as in any of Example 14-29, wherein the composition is provided for long-term treatment of cellular oxidative stress.
- a composition may include a combination of all or some, but not all, of the following ingredients:
- the amount of sunflower lecithin that may be included in the final composition is based on a percent by weight of the total weight of the final composition described herein.
- the composition may comprise ingredient (c) for example, in concentrations as follows:
- the L-glutathione reduced may comprise a purity before it is included in the composition in percentages as follows:
- any of the concentrations for ingredients (a) or (c), for example, as listed above may indicate the concentration for any of ingredients (b) and (d) thru (h), as listed above.
- an embodiment of the disclosure may comprise, for example, (a7) from 8% to 14% by weigh the total composition of L-glutathione reduced, and equal parts by weight of lemon essential oil and peppermint essential oil.
- the composition may comprise all, or any combination of but not all, of the ingredients (a) thru (h).
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Dispersion Chemistry (AREA)
- Botany (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
- This application is a continuation of U.S. application Ser. No. 15/955,608 filed Apr. 17, 2018 which claims the benefit under 35 U.S.C. § 119(e) of U.S. Provisional Application No. 62/460,725 filed Feb. 17, 2017, which are incorporated herein by reference in its entirety, including but not limited to those portions that specifically appear hereinafter, the incorporation by reference being made with the following exception: In the event that any portion of the above-referenced applications are inconsistent with this application, this application supercedes said portion of said above-referenced application.
- Not Applicable.
- The disclosure relates to compositions, methods and systems for improving free radical levels in a user and/or for the treatment of oxidative stress in a user. The compositions, methods, and systems of the disclosure may also be applicable in the treatment or support of the body's natural detoxification process and/or the treatment or support of the body's natural defense systems for combatting viruses, bacteria, heavy metal toxicity, radiation, certain medications, the process of aging, and the like.
- The present disclosure relates to a bio-effective nutraceutical composition. Specifically, the disclosure relates to a composition comprising reduced glutathione (GSH) manufactured to be substantially anaerobic and remaining in a reduced glutathione state at composition.
- What is needed are compositions, methods, and systems that are efficient for reducing free radical levels in a user and alleviating oxidative stress in the user. As will be seen, the disclosure provides such compositions, methods, and systems that can treat oxidative stress and improving the body's natural detoxification process and natural defense systems in an effective and elegant manner.
- Non-limiting and non-exhaustive implementations of the disclosure are described with reference to the following figures, wherein like reference numerals refer to like parts throughout the various views unless otherwise specified. Advantages of the disclosure will become better understood with respect to the following description and accompanying drawing where:
-
FIG. 1 illustrates the chemical structure of reduced glutathione (GSH) according to one implementation consistent with the teachings and principles of the disclosure; -
FIG. 2 illustrates the chemical oxidation reaction of reduced glutathione (GSH) to oxidized glutathione (GSSG) according to one implementation consistent with the teachings and principles of the disclosure; -
FIG. 3 illustrates a standard curve for reduced glutathione resulting from a short-term analysis of a clinical example consistent with the teachings and principles of the disclosure; -
FIG. 4 illustrates a standard curve for reduced glutathione resulting from a long-term analysis of a clinical example consistent with the teachings and principles of the disclosure; -
FIG. 5 illustrates concentrations of reduced glutathione resulting from a short-term analysis of a clinical example consistent with the teachings and principles of the disclosure; -
FIG. 6 illustrates concentrations of oxidized glutathione resulting from a short-term analysis of a clinical example consistent with the teachings and principles of the disclosure; -
FIG. 7 illustrates ratios of reduced glutathione to oxidized glutathione resulting from a short-term analysis of a clinical example consistent with the teachings and principles of the disclosure; -
FIG. 8 illustrates concentrations of reduced glutathione resulting from a long-term analysis of a clinical example consistent with the teachings and principles of the disclosure; -
FIG. 9 illustrates concentrations of oxidized glutathione resulting from a long-term analysis of a clinical example consistent with the teachings and principles of the disclosure; -
FIG. 10 illustrates ratios of reduced glutathione to oxidized glutathione resulting from a long-term analysis of a clinical example consistent with the teachings and principles of the disclosure; -
FIG. 11 illustrates ratios of reduced glutathione to oxidized glutathione resulting from a long-term analysis versus the baseline analysis of a clinical example consistent with the teachings and principles of the disclosure; -
FIG. 12 illustrates a schematic block diagram of a method for reducing oxidative stress in a user; and -
FIG. 13 illustrates a schematic block diagram of a method for reducing oxidative stress in a user. - The disclosure extends to compositions, methods, and systems for alleviating oxidative stress in a user and/or the reducing the levels of damaging free radicals in the user that may be accumulated due to viruses, bacteria, heavy metal toxicity, radiation, certain medications, the process of aging, and the like. The disclosure further extends to the anaerobic manufacture, packaging, and delivery of therapeutic amounts of bio-effective reduced glutathione (GSH).
- The disclosure extends to a highly bio-active composition for reducing oxidative stress in a user. The composition includes reduced glutathione and a deoxygenated water solvent, and the composition may be encapsulated in a phospholipid liposome structure to provide effective delivery to the user. The composition provides unexpectedly good results in maintaining reduced glutathione that is effective for alleviating cellular oxidative stress in a user and/or reducing a level of free radicals in the user's body. Compared with compositions known in the art that purport to provide reduced glutathione, the composition of the present disclosure provides unexpectedly good results in preventing the oxidation of reduced glutathione (GSH) to oxidized glutathione (GSSG) that is commonly found in purported GSH supplements known in the art. The composition provides unexpectedly good results in passing reduced glutathione through the mucosa membrane of a user directly into the user's bloodstream such that the user may receive effective relief from cellular oxidative stress and may reduce the levels of free radicals in the body. The composition of the disclosure provides unexpectedly good results in increasing levels of reduced glutathione in a user's blood serum over short-term and long-term periods. The composition further provides unexpectedly good results in improving the ratio of reduced glutathione to oxidized glutathione in a user's blood serum over short-term and long-term periods.
- The disclosure further extends to the anaerobic manufacture and packaging of a composition for reducing oxidative stress in a user. The composition provides reduced glutathione in a deoxygenated water solvent, wherein all or nearly all oxygen gas (O2) commonly found in water has been removed. The composition is encapsulated in a phospholipid liposome structure that provides some protection against oxidation of the reduced glutathione. The composition is further packaged in an airless dispenser. The composition provides high bio-activity in alleviating cellular oxidative stress in a user and reducing levels of free radicals in a user's body.
- In the following description of the disclosure, reference is made to the accompanying drawings, which form a part hereof, and in which is shown by way of illustration specific implementations in which the disclosure may be practiced. It is understood that other implementations may be utilized, and structural changes may be made without departing from the scope of the disclosure.
- In describing and claiming the subject matter of the disclosure, the following terminology will be used in accordance with the definitions set out below.
- As used herein, the terms “comprising,” “including,” “containing,” “characterized by,” and grammatical equivalents thereof are inclusive or open-ended terms that do not exclude additional, unrecited elements or method steps.
- As used herein, the phrase “consisting of” and grammatical equivalents thereof exclude any element, step, or ingredient not specified in the claim.
- As used herein, the phrase “consisting essentially of” and grammatical equivalents thereof limit the scope of a claim to the specified ingredients, materials or steps and those that do not materially affect the basic and novel characteristic or characteristics of the claimed disclosure.
- As used herein, “effective amount” means an amount of an ingredient or a component of the product that is nontoxic, but sufficient to provide the desired effect and performance at a reasonable benefit/risk ratio attending any dietary supplement or product. For example, an effective amount of a vitamin or mineral is an amount sufficient to prevent a deficiency thereof and to reduce the incidence of some adverse effects.
- Unless defined otherwise, all technical and scientific terms used herein have the same meanings as commonly understood by one of ordinary skill in the art to which this disclosure pertains and belongs.
- Oxidative stress, or high levels of free radicals in the body, is responsible for numerous health issues and is virtually impossible to avoid. Oxidative stress reflects an imbalance between the systemic manifestation of reactive oxygen species and the body's ability to readily detoxify the reactive intermediates or repair the resulting damage. Disturbances in the body's normal redox state of cells can cause toxic effects through the production of peroxides and free radicals that damage all components of a cell, including proteins, lipids, and DNA. Oxidative stress from oxidative metabolism causes base damage as well as strand breaks in DNA. Further, some reactive oxidative species act as cellular messengers in redox signaling. Thus, oxidative stress may cause disruptions in the body's normal mechanisms of cellular signaling. In humans, oxidative stress is thought to be involved in the development of attention deficit hyperactivity disorder, cancer, Parkinson's disease, Lafora disease, Alzheimer's disease, atherosclerosis, heart failure, myocardial infarction, fragile X syndrome, sickle-cell disease, licen planus, vitiligo, autism, infection, chronic fatigue syndrome, and depression, among other.
- Chemically, oxidative stress is associated with increased production of oxidizing species or a significant decrease in the effectiveness of antioxidant defenses, such as glutathione. Reduced glutathione (GSH) is often referred to as the body's master antioxidant. Glutathione is composed of three amino acids, including cysteine, glycine, and glutamine, and glutathione can be found in virtually every cell of the body. The highest concentration of glutathione is typically found in the liver where it serves a critical function in the body's natural detoxification process. This natural detoxification process is important for treating oxidative stress in the body and avoiding the production of damaging peroxides and free radicals.
- Glutathione is an important component of the body's natural defense system. Glutathione can be depleted by compositions or processes that are associated with free-radical damage, including for example, viruses, bacteria, heavy metal toxicity, radiation, certain medications, and the process of aging. The depletion of glutathione is associated with lower immune function, increased vulnerability to infection, and a reduction in the liver's ability to detoxify the body. As the generation of free radicals exceeds the body's ability to neutralize and eliminate them, oxidative stress occurs. A primary function of glutathione is to alleviate oxidative stress.
- Reduced glutathione is under tight homeostatic control both intracellularly and extracellularly. A dynamic balance is maintained between the synthesis of reduced glutathione, its recycling from oxidized glutathione, and its utilization.
- Reduced glutathione is utilized as a cofactor by multiple peroxidase enzymes to detoxify peroxides that are generated by oxygen radical attack on biological molecules. Reduced glutathione is further utilized as a cofactor by transhydrogenases to reduce oxidized centers on DNA, proteins, and other biomolecules. Reduced glutathione is further utilized as a cofactor by glutathione S-transferases (hereinafter “GST”) to conjugate reduced glutathione with endogenous substances (e.g. estrogens), exogenous electrophiles (e.g. arene oxides, unsaturated carbonyls, and organic halides), and diverse xenobiotics. Low GST activity may increase risk for disease, and paradoxically, some reduced glutathione conjugates can also be toxic.
- Reduced glutathione can be depleted by direct attack by free radicals and other oxidative agents. The homeostatic glutathione redox cycle attempts to keep reduced glutathione repleted as it is being consumed. Amounts available from foods are limited (less than 150 mg/day), and oxidative depletion can outpace synthesis.
- The liver is the largest reservoir of reduced glutathione. The parenchymal cells synthesize reduced glutathione for P450 conjugation and numerous other metabolic requirements, then export reduced glutathione as a systemic source of SH-reducing power. Reduced glutathione is carried in the bile to the intestinal luminal compartment. Epithelial tissues of the kidney tubules, intestinal lining, and lungs have substantial P450 activity and a modest capacity to export reduced glutathione. However, it will be appreciated that glutathione exists in the intracellular and extracellular spaces of all cells and is present throughout the body.
- Equivalents of reduced glutathione circulate in the blood predominately as cystine (i.e., the oxidized and more stable form of cysteine.) Cells import cystine from the blood, reconvert it to cysteine, and form it to synthesize reduced glutathione. Conversely, inside the cell, reduced glutathione assists in re-reducing oxidized forms of other antioxidants such as ascorbate and alpha-tocopherol.
- Reduced glutathione is an important cell protectant; it directly quenches reactive hydroxyl free radicals, other oxygen-centered free radicals, and radical centers on DNA and other biomolecules. Reduced glutathione is a primary protectant of the skin, lens, cornea, and retina against radiation damage and other biochemical foundations of P450 detoxification in the liver, kidneys, lungs, intestinal, epithelia, and other organs.
- Reduced glutathione is the essential cofactor for many enzymes that require thiol-reducing equivalents, and it helps keep redox-sensitive active sites on enzymes in the necessary reduced state. Higher-order thiol cell systems, the metallothioneins, thioredoxins, and other redox regulator proteins are ultimately regulated by the levels of reduced glutathione, and the ratio of reduced glutathione to oxidized glutathione. The balance of reduced and oxidized glutathione is crucial to homeostasis in the body, to stabilizing the cellular biomolecular spectrum, and to facilitating cellular performance and survival. Reduced glutathione and its metabolites interface with energetics and neurotransmitter syntheses through several prominent metabolic pathways. Reduced glutathione availability down-regulates the pro-inflammatory potential of leukotrienes and other eicosanoids. Recently discovered S-nitroso metabolites, generated in vivo from reduced glutathione and nitric oxide (NO), further diversify the impact of reduced glutathione on the body's metabolism.
- According to the present disclosure, a reduced glutathione supplement may be manufactured in an anaerobic environment using one or more non-reactive gasses to ensure the maintenance of the reduced form, rather than the oxidized form, of glutathione. Additionally, de-oxygenated water may be used during the manufacturing process and as a carrier for the supplement. By using de-oxygenated water, very little of the oxygen is available in the water to convert the reduced glutathione to oxidized glutathione.
- In an embodiment of the disclosure, a composition for reducing oxidative stress in a user is disclosed. The composition includes an effective amount of reduced glutathione for reducing oxidative stress in the user, and a deoxygenated water solvent. In an embodiment, the composition is encapsulated in a phospholipid liposome structure. In an embodiment, the composition is packaged in an airless dispenser configured to maintain an anaerobic environment.
- In a further embodiment of the disclosure, a method of reducing oxidative stress in a user is disclosed. The method includes providing a composition to the user, wherein the composition comprises an effective amount of reduced glutathione for reducing oxidative stress in the user and a deoxygenated water solvent. In an embodiment, the composition is encapsulated in a phospholipid liposome structure and the composition is packaged in an airless dispenser configured to maintain an anaerobic environment.
- In a further embodiment of the disclosure, a method for manufacturing a composition for reducing oxidative stress in a user is disclosed. The method includes mixing reduced glutathione powder and deoxygenated water in an anaerobic environment to form a reduced glutathione solution. The method includes packaging the reduced glutathione solution in an airless dispenser in an anaerobic environment such that the reduced glutathione is not substantially exposed to an oxygen source from manufacture to dispensing.
- In an embodiment of the disclosure, reduced glutathione is dissolved in a deoxygenated water solvent. The deoxygenated water solvent has had dissolved oxygen (O2) gasses removed from the water. Various techniques for removing dissolved oxygen from water are known in the art, including for example, boiling water at atmospheric pressure, boiling water at reduced pressure, purging water with nitrogen gas (N2), argon gas (Ar), or other inert gas, and sonication of the water under reduced pressure. Additionally, water deoxygenation may be performed by bio reactive processes including, for example, yeast-based bio reactive processes. In an embodiment, highly pure deoxygenated water is utilized in combination with other components of the composition disclosed herein.
- In an embodiment, the composition is encapsulated in a liposome structure. The liposome structure may be a spherical lipid-based vesicle constructed from sunflower-based lecithin rich in plant-based phospholipids. The liposome structure may have a hollow core including an aqueous solution of the reduced glutathione in deoxygenated water with other components as disclosed herein. The liposome structure may provide enhanced and targeted delivery to a user through the user's oral, esophageal, and gastrointestinal mucosa lining. It should be appreciated that the liposome structure may comprise any suitable liposome structure and is not limited to a spherical lipid-based vesicle from sunflower-based lecithin. Sunflower-based lecithin has a low affinity for allergenic response as compared to soy lecithin and may be advantageous for certain users who are disposed to allergenic reactions.
- The liposome structure of the disclosure comprises a natural positive charge and has a high affinity for mucosal binding. In an embodiment, the liposome structure is configured to provide gradual delivery of the deoxygenated aqueous reduced glutathione solution from the liposome core through the mucosal lining of a user into the user's bloodstream.
- In an embodiment, the phospholipids in the lecithin are responsible for organized formation of a liposome vesicle by providing lipid molecules, especially phosphatidylcholine, containing a hydrophilic head and hydrophobic tail, that has a binding capacity to form a spherical vesicle including at least one lipid bilayer. The hydrophilic head is located on an outer shell and the hydrophobic tail is oriented toward an inner surface of the vesicle shell. A liposome has an aqueous solution core surrounded by a hydrophobic membrane in the form of a lipid bilayer. Hydrophilic solutes, such as reduced glutathione, are dissolved in the core and cannot readily pass through the lipid bilayer. To deliver the molecules to a site of action, the lipid bilayer may fuse with other bilayers, such as a cell wall, and deliver the liposome contents.
- In an embodiment, the liposome structure is defined as a distribution of Small Unilayer Vesicles (SUV) and Large Unilayer Vesicles (LUV). SUV liposomes are defined as a single unilayer vesicle having a diameter between about 20 nm to about 100 nm. LUV liposomes are defined as a single inlayer vesicle having a diameter between about 100 nm to about 400 nm. In an embodiment, the majority of the liposomes in the formulation are of the SUV type. In an embodiment, the composition includes a higher loading of lecithin to provide more phospholipids to maximize the number of liposomes in the composition. In an embodiment, the liposomes comprise more than 8 wt % the total composition. In an embodiment, the liposomes comprise more than l0 wt % the total composition. An increased liposomal population may maximize the encapsulation of the deoxygenated aqueous reduced glutathione and solute to a theoretical efficiency of about 50% of the aqueous medium.
- In an embodiment, liposomes of the composition primarily perform the function of targeted delivery and slow release of the deoxygenated aqueous reduced glutathione. Further, some oxidative protection is afforded by the liposome vesicle in the form of an oxygen permeability rate limited reducing oxidation of the internal contents after dispensing the composition. During storage in the consumer liquid product package, which in an embodiment includes an airless dispenser, eventually all components of the composition will reach a similar oxygen saturation and level.
- Referring now to the figures,
FIG. 1 illustrates thechemical structure 100 of reduced glutathione. As illustrated, reduced glutathione comprisesglutamic acid 102,cysteine 104, andglycine 106. Reduced glutathione (GSH) is a linear tripeptide of L-glutamine, L-cysteine, and glycine. Reduced glutathione is technically referred to as N-L-gamma-glutamyl-cysteinyl glycine or L-glutathione. The molecule includes a sulfhydryl (SH) group on the cysteinyl portion that accounts for its strong electron-donating character that enables glutathione to be effective in reducing oxidative stress in the body. Glutathione is oxidized as an electron is lost, and two such molecules (with a lost electron) become linked or dimerized by a disulfide bridge. The dimerized molecules form glutathione disulfide or oxidized glutathione (GSSG). The linkage is reversible upon re-reduction. - The synthesis of reduced glutathione includes two closely linked and enzymatically-controlled reactions that utilize adenosine triphosphate (ATP). First, cysteine and glutamate are combined by gamma-glutamyl cysteinyl synthetase. Second, reduced glutathione synthetase combines gamma-glutamylcysteine with glycine to generate reduced glutathione. As the levels of reduced glutathione rise, the processes are self-limited against further production of reduced glutathione. Otherwise, cysteine availability is usually rate-limiting. Fasting, protein-energy malnutrition, and other dietary amino acid deficiencies limit the synthesis of reduced glutathione. The recycling of reduced glutathione is catalyzed by glutathione disulfide reductase, which uses reducing equivalents from nicotinamide adenine dinucleotide phosphate (NADPH) to reconvert oxidized glutathione to glutathione disulfide. The reducing power of ascorbate helps conserve systemic reduced glutathione.
-
FIG. 2 illustrates theoxidation reaction 204 of reduced glutathione (GSH) 202 to oxidized glutathione (GSSG) 208. Thereaction 204 produces two electrons and two protons as illustrated at 206. - In an embodiment of the disclosure, a composition is provided to a user. The composition includes 99.9% purity reduced glutathione powder. The reduced glutathione powder is solubilized in a deoxygenated water solvent and encapsulated in a plant-based phospholipid liposome structure. The composition includes an effective amount of stevia, natural lemon essential oil, and natural peppermint essential for improving the overall flavor of the composition for human oral consumption. In an embodiment, the composition includes from about 525 mg to about 575 mg of reduced glutathione per 4 g of solution.
- In an embodiment, the resulting liquid composition is packaged in an airless dispenser that is configured to maintain the composition in an anaerobic environment. As such, the airless dispenser protects the reduced glutathione from degradation and conversion to oxidized glutathione. Applicant recognizes that previous purported supplements including reduced glutathione suffer from a sulfur smell due to the strong oxidation of reduced glutathione. As such, the airless dispenser extends the effective shelf-life of the reduced glutathione in the present disclosure by substantially eliminating contact of the reduced glutathione with oxygen, even after first use of the composition. Applicant recognizes that other forms of packaging and delivery result in the reduced glutathione making contact with oxygen and thus rapidly degrading and oxidizing into oxidized glutathione, even if a successful manufacture of reduced glutathione is initially achieved.
- In one study conducted to test the effectiveness of a composition comprising reduced glutathione as disclosed above, the bio-effectiveness and availability of reduced glutathione in the body was greatly enhanced compared with purported GSH supplements known in the art. The composition provided unexpectedly good results given that purported GSH supplements known in the art in fact fail to deliver reduced glutathione to the user.
- In one clinical study, a composition including reduced glutathione in a deoxygenated water solvent was provided to a user. The composition was encapsulated in a phospholipid liposome structure and packaged and delivered from an airless dispenser. The composition included 550±2 mg of reduced glutathione per 4 g of solution. The composition was provided to three human volunteers as a liquid-based oral supplement, and it was provided to one human volunteer as a liquid-based topical treatment to be applied topically. The human serum levels of reduced glutathione and oxidized glutathione were sampled initially before ingestion to establish a baseline level, and the serum levels were again sampled three times over eight hours after ingestion or application of the composition. The participants continued to take the composition once every morning at least thirty minutes before meals for four weeks. The serum levels of the participants were sampled once each week during the four-week study period to collect data for long-term effects of the composition.
- Each participant experienced a short-term increase in serum levels of reduced glutathione equal to at least a 30% increase in the presence of reduced glutathione in the serum. Each participant experienced a long-term progressive reduction of oxidized glutathione equal to at least a 30% reduction in the presence of oxidized glutathione in the serum. As discussed previously, the ratio of reduced glutathione to oxidized glutathione is an important and well-understood marker for cellular oxidative stress. The results of the clinical example indicate that the composition was bioavailable unlike other pill and capsule delivery forms of purported GSH supplements. Further, the composition provided long-term reduction in systemic cellular oxidative stress in each of the participants.
- In the above-referenced study, four persons agreed to participate. The participants included one male and one female ranging in age from 23 to 83 years of age. The participants were assigned a number from #1 to #4 as follows: (1) 61-year-old female, (2) 55-year-old male, (3) 23-year-old female, and (4) 83-year-old female. Each of the participants was permitted to each the morning of the first serum collection but refrained from taking antioxidant dietary supplements during the course of the four-week study period. The participants' blood was collected for baseline measurements at approximately 8:00 AM by intravenous puncture. The serum was extracted, processed, and frozen for later analysis. After the collection of the baseline serum sample, the participants immediately consumed the composition by dispensing 4 mL of the liquid composition into their mouth and swishing for 15-20 seconds before swallowing. The participants refrained from drinking for 15 minutes afterward. The participant who used the product topically applied approximately the same amount of the composition onto the abdomen and soft areas under the arms. Samples of the participants' blood were against collected at 2 hours, 6 hours, and 8 hours after the first collection. The participants consumed the composition one time per day in the morning for a four-week period. The participants' blood was collected each week at exactly seven-day intervals for four weeks at approximately 10:00 AM. The participants were instructed to consume the composition four hours prior to collection. The serum was extracted, processed, and frozen for later analysis. All serum samples were assayed within thirty days of collection.
- Analysis of the Serum Samples.
- The serum samples were analyzed to determine the levels of reduced glutathione and oxidized glutathione. The serum samples were analyzed using the BioVision (Milpitas, Calif.) Glutathione Fluorometric Assay Kit (GSH, GSSG, and Total) k264. Wasatch Scientific Laboratories in Murray, Utah, USA was contracted to perform the assay using the BioVision fluorometric kit and method. Whole blood samples were collected and immediately centrifuged to separate the serum from the red blood cells and heavier components. Approximately 120 μL of serum was added to 40 μL of an ice-cold perchloric acid PCA buffer in a 1 mL aliquot. The solution was vortexed and stored on ice for five minutes. The solution was centrifuged at 13,000 G for two minutes, and the supernatant was collected and frozen at −60 degC.
-
FIG. 3 illustrates a standard curve for reduced glutathione for the short-term analysis. The standard curve for reduced glutathione and oxidized glutathione were created, and then the prepared serum samples were tested at two dilutions to determine the optimal dilution for the best dynamic resolution of the assay. The samples were processed and assayed in duplicate pairs at the chosen dilution. The results of each pair were reviewed and compared for repeatability and best-fit samples were used.FIG. 3 illustrates a mass of reduced glutathione (GSH) in nanograms on the x-axis plotted against the relative fluorescence units (RFU) on the y-axis. -
FIG. 4 illustrates a standard curve for reduced glutathione for the long-term analysis. The standard curve for reduced glutathione and oxidized glutathione were created, and then the prepared serum samples were tested at two dilutions to determine the optimal dilution for the best dynamic resolution of the assay. The samples were processed and assayed in duplicate pairs at the chosen dilution. The results of each pair were reviewed and compared for repeatability and best-fit samples were used.FIG. 3 illustrates a mass of reduced glutathione (GSH) in nanograms on the x-axis plotted against the relative fluorescence units (RFU) on the y-axis. The results of the assay were compiled and displayed in tabular and graphical form. In addition, ratiometric results of reduced glutathione (GSH) and oxidized glutathione (GSSG) were created for each sample. -
FIG. 5 illustrates concentrations of reduced glutathione for each of the four aforementioned participants for the short-term analysis.FIG. 5 illustrates concentrations in μg/mL for each of four possible serum draws for each of the four participants. Draw one is the baseline draw. Draw two was taken at the baseline plus four hours. Draw three was taken at the baseline plus six hours. Draw four was taken at the baseline plus eight hours. As illustrated inFIG. 5 , all participants in the short-term analysis experienced an increase in serum levels of reduced glutathione. The increase concentration of reduced glutathione appeared to peak at approximately six to eight hours after ingestion. The increase in reduced glutathione was on average 30% above baseline levels. Participant one, a female, applied the composition topically and experienced elevated serum levels of reduced glutathione. -
FIG. 6 illustrates concentrations of oxidized glutathione for each of the four aforementioned participants for the short-term analysis.FIG. 6 illustrates concentrations in μg/mL for each of four possible serum draws for each of the four participants. Draw one is the baseline draw. Draw two was taken at the baseline plus four hours. Draw three was taken at the baseline plus six hours. Draw four was taken at the baseline plus eight hours. Participant one, a female, applied the composition topically and experienced elevated serum levels of reduced glutathione. As illustrated inFIG. 6 , concentrations of oxidized glutathione appeared to respond differently for each participant. The most significant change in levels of oxidized glutathione was an almost 50% reduction in participant one who applied the composition topically. In participants three and four, the levels of oxidized glutathione on average reduced slightly from baseline. -
FIG. 7 illustrates the ratios of reduced glutathione to oxidized glutathione for each of the participants for the short-term analysis. As illustrated inFIG. 7 , the composition provided a short-term antioxidant benefit to each of the participants. The reduced/oxidized glutathione ratio is an accepted standard to measure cellular oxidative stress. This study illustrates the redox ratio trend over time. After ingestion, each participant experienced an increase in the redox ratio compared to the baseline, even eight hours after consuming or applying the composition. This study demonstrates bio-utilization of the redox ratio. -
FIG. 8 illustrates concentrations of reduced glutathione for each of the four aforementioned participants for the long-term analysis.FIG. 8 illustrates concentrations in μg/mL for each of three weekly serum draws for each of the four participants. Draw one (not shown due to laboratory error) was taken at 10:00 AM exactly one week after ingestion or application of the composition. Draw two occurred at 10:00 AM two weeks after ingestion or application of the composition. Draw three occurred at 10:00 AM exactly three weeks after ingestion or application of the composition. Draw four occurred at 10:00 AM exactly four weeks after ingestion or application of the composition. The human serum samples were assayed for concentrations of reduced and oxidized glutathione. Participant one, a female, applied the composition topically and participants two, three, and four ingested orally a liquid-based composition. - As illustrated in
FIG. 8 , the participants' serum levels of reduced glutathione show mixed results. Participants one and three demonstrates levels of reduced glutathione that are very close to the baseline levels without significant increase. Participants two and four demonstrated long-term increase in levels of reduced glutathione equal to approximately 20-22%. The long-term serum levels of reduced glutathione when viewed alone showed positive results in participants two and four. -
FIG. 9 illustrates concentrations of oxidized glutathione for each of the four aforementioned participants for the long-term analysis.FIG. 9 illustrates concentrations in μg/mL for each of three weekly serum draws for each of the four participants. Draw one (not shown due to laboratory error) was taken at 10:00 AM exactly one week after ingestion or application of the composition. Draw two occurred at 10:00 AM two weeks after ingestion or application of the composition. Draw three occurred at 10:00 AM exactly three weeks after ingestion or application of the composition. Draw four occurred at 10:00 AM exactly four weeks after ingestion or application of the composition. The human serum samples were assayed for concentrations of reduced and oxidized glutathione. Participant one, a female, applied the composition topically and participants two, three, and four ingested orally a liquid-based composition. - As illustrated in
FIG. 9 , each of the four participants experienced a significant decrease in long-term concentrations of oxidized glutathione (GSSG). As discussed previously, reduced glutathione is oxidized inside cells and converted to oxidized glutathione according to thereaction 200 illustrated inFIG. 2 . A portion of the oxidized glutathione is shuttled out of the cells and into the intracellular space and into the blood. When the ratio of reduced/oxidized glutathione is calculated, a true reduction is cellular oxidation is evidence. -
FIG. 10 illustrates the ratios of reduced glutathione to oxidized glutathione for each of the four aforementioned participants for the long-term analysis. As illustrated inFIG. 10 , each of the participants experienced a sustained and cumulative decrease in oxidative stress. The reduced/oxidized glutathione redox ratio increased for all participants over the four weeks of ingesting or applying the composition. Applicant notes that participant three and participant four represent a wide age and health gap, where one is a 23-year-old healthy female and the other is an 83-year old female with health issues due to age. The composition had a positive long-term effect in both the young participant and the older participant, where the older participant experienced a greater rise in the redox ratio. The data further shows that participant one experienced a redox benefit, even by applying the product topically. Applicant notes that participant one only applied about one-third of the dose compared to the oral participants, not following specific dosing instructions. The results for all participants clearly demonstrates the benefits of the novel composition comprising reduced glutathione that is disclosed herein. -
FIG. 11 illustrates the ratios of reduced glutathione to oxidized glutathione for each of the participants for the long-term analysis versus the baseline analysis.FIG. 11 illustrates a comparison of the change in redox over time as a result of supplementation with the composition disclosed herein. As illustrated inFIG. 11 , all participants experienced a net average increase above baseline redox ratios, with participant two (55-year-old male) and participant four (83-year-old female) experiencing the greatest increase. Applicant notes that it is anticipated that participant one (61-year-old female) would have experienced a greater result if the dosage requirements for topical application were followed more consistently. - The effects of the novel composition comprising reduced glutathione that is disclosed herein indicate a bioavailability of reduced glutathione and its short-term and long-term benefits in the human body as indicated in the serum concentrations of reduced glutathione (GSH) and oxidized glutathione (GSSG). All participants experienced a noticeable increase in GSH/GSSG redox ratio indicating a true reduction in cellular oxidative stress, with the older participants (age 55-83) experiencing higher ratios. This is consistent with the assumption that older participants have a greater amount of cellular oxidative stress to be reduced.
- The results of the clinical example demonstrate conclusively that the composition disclosed herein is effectively delivering reduced glutathione. The composition includes reduced glutathione and a deoxygenated water solvent. The composition is manufactured and packaged in an anaerobic environment, in stark contrast with previous supplements known in the art that purport to deliver reduced glutathione but instead deliver oxidized glutathione. The careful maintenance of an anaerobic condition, as disclosed herein, provides the unexpected result (given all prior failures) of a composition that genuinely comprises reduced glutathione. The composition disclosed herein provides increased levels of reduced glutathione, reduced cellular oxidative stress, and provides all the appurtenant benefits.
- It should be appreciated that in various embodiments, dosage amounts may be adjusted depending on the effect on any given individual, as well as the biometrics of that individual. For example, a larger person may require a higher dosage than a smaller person. Similarly, a person suffering from an acute condition may benefit from a higher dose for a time until the condition is controlled, at which point a lower dose may provide sufficient management over time.
- Referring now to
FIG. 12 , a schematic block diagram of amethod 1200 for reducing oxidative stress in a user is illustrated. Themethod 1200 begins and a composition is provided to a user at 1202. The composition comprises an effective amount of reduced glutathione for reducing oxidative stress in the user and a deoxygenated water solvent. -
FIG. 13 illustrates a schematic block diagram of amethod 1300 for reducing oxidative stress in a user. Themethod 1300 beings and a composition is provided to a user at 1302. The composition includes an effective amount of reduced glutathione for reducing oxidative stress in the user, a deoxygenated water solvent, an effect amount of one or more preservatives, and an effective amount of one or more natural flavoring components for improving an overall flavor of the composition. The composition is such that the reduced glutathione comprises from about 8% to about 14% by weight of the total composition. The composition is such that the reduced glutathione comprises a purity from about 98% to about 99.9% purity. The composition is encapsulated in a phospholipid liposome structure. The composition is packaged in an airless dispenser configured to maintain an anaerobic environment. - In one embodiment, the composition may be provided for the treatment of cellular oxidative stress. When the composition is provided for the treatment of cellular oxidative stress, it may be ingested orally or administered topically. Applicant notes that in further embodiments the composition may be administered intravenously or intramuscularly, or in a tablet or powder form without departing from the scope of the disclosure.
- In one embodiment, the composition is provided for the treatment of acute levels of free radicals in the body. In such an embodiment, the composition may be prepared for immediate intravenous or intramuscular administration. The composition may further or alternatively be provided for oral ingestion or topical application. In such an embodiment, the composition may be provided for regular administration after acute levels of free radicals in the body have been treated and reduced to safe levels.
- In one embodiment, the composition is provided for the treatment of acetaminophen overdose. The molecule known as N-acetylcysteine (hereinafter “NAC”) is known in the art for the treatment of acetaminophen overdose. Pharmaceutical NAC is primarily used in medical settings for respiratory conditions, to manage acetaminophen overdose, and to prevent radio-contrast-induced nephropathy. However, the half-life of NAC is approximately 5.6 hours, and 30% of NAC is renally excreted by the body. Orally administered or inhaled NAC is associated with drowsiness, stomatitis, clamminess, rhinorrhea, and hemoptysis, and NAC is a category B pregnancy risk. In contrast with NAC, where the half-life is extremely short and the molecule is unstable, the shelf-life of the composition disclosed herein is at least one year. Therefore, the composition disclosed herein provides an alternative to NAC that is shelf-stable for an extended period and demonstrates high viability and efficacy.
- In one embodiment, a 99.9% purity reduced glutathione powder is solubilized in deoxygenated water and encapsulated in a plant-based phospholipid liposome structure. In the embodiment, the composition includes from about 8% to about 14% by weight reduced glutathione. The composition includes from about 4% to about 11% by weight sunflower lecithin. The composition includes from about 0.2% to about 0.6% by weight lemon essential oil. The composition includes from about 0.1% to about 0.5% peppermint essential oil. The composition includes from about 0.01% to about 0.25% stevia extract. The composition includes sodium benzoate and potassium sorbate.
- In an embodiment of the disclosure, the composition includes highly pure L-glutathione reduced. In an embodiment of the disclosure, the reduced glutathione comprises a purity from about 98% to about 99.9% purity. In an embodiment, the purity is from about 90% to about 99.9% purity. In an embodiment, the purity is from about 95% to about 99.9% purity. In an embodiment, the purity is from about 99.0% to about 99.9% purity. It should be appreciated that various ranges of purity may be extracted from any of the aforementioned ranges as if those ranges were disclosed explicitly.
- In an embodiment of the disclosure, the composition includes sunflower lecithin. Lecithin is a fat found in a plurality of food products. Sunflower lecithin is a phospholipid comprising phosphatidylcholine, phosphatidylinositol, phosphatidylethanolamine, and omega-6 linoleic acid. Sunflower lecithin is associated with processing fats and supporting cell membranes. In an embodiment of the disclosure, the sunflower lecithin is provided for encapsulating the composition and protecting the reduced glutathione component.
- In an embodiment of the disclosure, the composition includes lemon essential oil. Lemon essential oil may be provided to improve an overall flavor of the composition. As disclosed, oxidized glutathione provides a sulfur smell that may be pungent or off-putting to a user. Additionally, the composition of the present disclosure may oxidize with oxygen in the air when the composition is being ingested, and the oxidized may cause the composition to become unpalatable to the user immediately before the user ingests the composition. The lemon essential oil may be provided to counteract the sulfur smell of the oxidized glutathione and increase the flavor of the composition.
- In an embodiment of the disclosure, the composition includes peppermint essential oil. As discussed previously with respect to the lemon essential oil, the peppermint essential oil may be provided to improve the overall flavor of the composition and mask a sulfur smell arising from the oxidation of the reduced glutathione.
- In an embodiment of the disclosure, the composition includes stevia extract. As discussed previously with respect to the lemon essential oil and/or the peppermint essential oil, the stevia extract may be provided to improve the overall flavor of the composition and mask a sulfur smell arising from the oxidation of the reduced glutathione.
- In an embodiment of the disclosure, the composition includes sodium benzoate. Sodium has a chemical formula of NaC7H5O2. Sodium benzoate is known as a food preservative and has an E number of E211. Sodium benzoate is the sodium salt of benzoic acid and exists in the form when dissolved in water. As a food additive, sodium benzoate is bacteriostatic and fungistatic under acidic condition. Sodium benzoate is included in the composition as a preservative in an embodiment of the disclosure.
- In an embodiment of the disclosure, the composition includes potassium sorbate. Potassium sorbate has a chemical formula of CH3CH═CH—CH=CH—CO2K. Potassium sorbate is a known food preservative and has an E number of E202. Potassium sorbate is known for inhibiting molds and yeasts in a variety of foods and liquids. Potassium sorbate is included in the composition as a preservative in an embodiment of the disclosure.
-
Chart 1 below shows an example embodiment of the composition. Components were dissolved in deoxygenated water and encapsulated in a plant-based phospholipid liposome structure. The composition was packaged and stored in an airless dispenser. -
CHART 1Component Weight Percent Total Composition L-glutathione reduced 14.00 Sunflower lecithin 10.50 Lemon essential oil 0.40 Peppermint essential oil 0.25 Sodium benzoate 0.10 Potassium sorbate 0.10 Stevia extract 0.10 -
Chart 2 below shows an example embodiment of the composition. Components were dissolved in deoxygenated water and encapsulated in a plant-based phospholipid liposome structure. The composition was packaged and stored in an airless dispenser. -
CHART 2Component Weight Percent Total Composition L-glutathione reduced 10.00 Sunflower lecithin 10.50 Lemon essential oil 0.40 Peppermint essential oil 0.25 Sodium benzoate 0.10 Potassium sorbate 0.10 Stevia extract 0.10 -
Chart 3 below shows an example embodiment of the composition. Components were dissolved in deoxygenated water and encapsulated in a plant-based phospholipid liposome structure. The composition was packaged and stored in an airless dispenser. -
CHART 3Component Weight Percent Total Composition L-glutathione reduced 8.00 Sunflower lecithin 10.50 Lemon essential oil 0.40 Peppermint essential oil 0.25 Sodium benzoate 0.10 Potassium sorbate 0.10 Stevia extract 0.10 -
Chart 4 below shows an example embodiment of the composition. Components were dissolved in deoxygenated water and encapsulated in a plant-based phospholipid liposome structure. The composition was packaged and stored in an airless dispenser. -
CHART 4Component Weight Percent Total Composition L-glutathione reduced 14.00 Sunflower lecithin 4.00 Lemon essential oil 0.40 Peppermint essential oil 0.25 Sodium benzoate 0.10 Potassium sorbate 0.10 Stevia extract 0.10 - Chart 5 below shows an example embodiment of the composition. Components were dissolved in deoxygenated water and encapsulated in a plant-based phospholipid liposome structure. The composition was packaged and stored in an airless dispenser.
-
CHART 5 Component Weight Percent Total Composition L-glutathione reduced 14.00 Sunflower lecithin 11.00 Lemon essential oil 0.40 Peppermint essential oil 0.25 Sodium benzoate 0.10 Potassium sorbate 0.10 Stevia extract 0.10 - Chart 6 below shows an example embodiment of the composition. Components were dissolved in deoxygenated water and encapsulated in a plant-based phospholipid liposome structure. The composition was packaged and stored in an airless dispenser.
-
CHART 6 Component Weight Percent Total Composition L-glutathione reduced 14.00 Sunflower lecithin 10.50 Lemon essential oil 0.20 Peppermint essential oil 0.25 Sodium benzoate 0.10 Potassium sorbate 0.10 Stevia extract 0.10 -
Chart 7 below shows an example embodiment of the composition. Components were dissolved in deoxygenated water and encapsulated in a plant-based phospholipid liposome structure. The composition was packaged and stored in an airless dispenser. -
CHART 7Component Weight Percent Total Composition L-glutathione reduced 14.00 Sunflower lecithin 10.50 Lemon essential oil 0.60 Peppermint essential oil 0.25 Sodium benzoate 0.10 Potassium sorbate 0.10 Stevia extract 0.10 -
Chart 8 below shows an example embodiment of the composition. Components were dissolved in deoxygenated water and encapsulated in a plant-based phospholipid liposome structure. The composition was packaged and stored in an airless dispenser. -
CHART 8Component Weight Percent Total Composition L-glutathione reduced 14.00 Sunflower lecithin 10.50 Lemon essential oil 0.40 Peppermint essential oil 0.10 Sodium benzoate 0.10 Potassium sorbate 0.10 Stevia extract 0.10 - Chart 9 below shows an example embodiment of the composition. Components were dissolved in deoxygenated water and encapsulated in a plant-based phospholipid liposome structure. The composition was packaged and stored in an airless dispenser.
-
CHART 9 Component Weight Percent Total Composition L-glutathione reduced 14.00 Sunflower lecithin 10.50 Lemon essential oil 0.40 Peppermint essential oil 0.50 Sodium benzoate 0.10 Potassium sorbate 0.10 Stevia extract 0.10 - Example 1 is a composition for reducing oxidative stress in a user. The composition includes an effective amount of reduced glutathione for reducing oxidative stress in the user, and deoxygenated water solvent.
- Example 2 is a composition as in Example 1, wherein the composition is encapsulated in a phospholipid liposome structure.
- Example 3 is a composition as in any of Examples 1-2, wherein the composition is packaged in an airless dispenser configured to maintain an anaerobic environment.
- Example 4 is a composition as in any of Examples 1-3, wherein the reduced glutathione comprises from about 8% to about 14% by weight of the total composition.
- Example 5 is a composition as in any of Examples 1-4, wherein the composition comprises from about 500 mg to about 600 mg reduced glutathione per 4 g of the composition.
- Example 6 is a composition as in any of Examples 1-5, wherein the reduced glutathione comprises a purity from about 98% to about 99.9% purity.
- Example 7 is a composition as in any of Examples 1-6, further comprising an effective amount of sodium benzoate for preserving the composition.
- Example 8 is a composition as in any of Examples 1-7, further comprising an effective amount of potassium sorbate for preserving the composition.
- Example 9 is a composition as in any of Examples 1-8, further comprising an effective amount of one or more natural flavoring components selected from a list comprising: lemon essential oil, peppermint essential oil, monk fruit extract, agave, honey, natural cane sugar, glucose, fruit concentrate, natural fruit powder, spearmint essential oil, wintergreen essential oil, orange essential oil, tangerine essential oil, lavender essential oil, and stevia extract.
- Example 10 is a composition as in any of Examples 1-9, wherein the composition is prepared for liquid oral consumption.
- Example 11 is a composition as in any of Examples 1-10, wherein the composition is prepared for topical application.
- Example 12 is a composition as in any of Examples 1-11, wherein the composition is prepared for intravenous or intramuscular administration.
- Example 13 is a composition as in any of Examples 1-12, wherein the reduced glutathione comprises from about 4 g to about 20 g per 100 mL of the deoxygenated water solvent.
- Example 14 is a method of reducing oxidative stress in a user. The method includes providing a composition to the user, wherein the composition includes an effective amount of reduced glutathione for reducing oxidative stress in the user, and a deoxygenated water solvent.
- Example 15 is a method as in Example 14, wherein the composition is encapsulated in a phospholipid liposome structure.
- Example 16 is a method as in any of Example 14-15, wherein the composition is packaged in an airless dispenser configured to maintain an anaerobic environment.
- Example 17 is a method as in any of Example 14-16, wherein the reduced glutathione comprises from about 8% to about 14% by weight of the total composition.
- Example 18 is a method as in any of Example 14-17, wherein the composition comprises from about 500 mg to about 600 mg reduced glutathione per 4 g of the composition.
- Example 19 is a method as in any of Example 14-18, wherein the reduced glutathione comprises a purity from about 98% to about 99.9% purity.
- Example 20 is a method as in any of Example 14-19, wherein the reduced glutathione comprises a purity from about 99.0% to about 99.9% purity.
- Example 21 is a method as in any of Example 14-20, wherein the composition further comprises an effective amount of sodium benzoate for preserving the composition.
- Example 22 is a method as in any of Example 14-21, wherein the composition further comprises an effective amount of potassium sorbate for preserving the composition.
- Example 23 is a method as in any of Example 14-22, wherein the composition further comprises an effective amount of one or more natural flavoring components selected from a list comprising: lemon essential oil, peppermint essential oil, monk fruit extract, agave, honey, natural cane sugar, glucose, fruit concentrate, natural fruit powder, spearmint essential oil, wintergreen essential oil, orange essential oil, tangerine essential oil, lavender essential oil, and stevia extract.
- Example 24 is a method as in any of Example 14-23, wherein the composition is provided to the user for liquid oral consumption.
- Example 25 is a method as in any of Example 14-24, wherein the composition is provided to the user for topical administration.
- Example 26 is a method as in any of Example 14-25, wherein the composition is provided to the user for intravenous or intramuscular administration.
- Example 27 is a method as in any of Example 14-26, wherein the reduced glutathione comprises from about 4 g to about 20 g per 100 mL of the deoxygenated water solvent.
- Example 28 is a method as in any of Example 14-27, wherein the composition is provided to the user for short-term treatment of cellular oxidative stress.
- Example 29 is a method as in any of Example 14-28, wherein the composition increases blood-serum levels of reduced glutathione in the user by at least 25%.
- Example 30 is a method as in any of Example 14-29, wherein the composition is provided for long-term treatment of cellular oxidative stress.
- According to one or more embodiments of the disclosure, a composition may include a combination of all or some, but not all, of the following ingredients:
- (a) L-glutathione reduced;
- (b) deoxygenated water;
- (c) sunflower lecithin;
- (d) lemon essential oil;
- % (e) peppermint essential oil;
- (f) sodium benzoate;
- (g) potassium sorbate; and/or
- (h) stevia extract.
- Other embodiments of the composition may comprise, for example, concentrations of L-glutathione reduced as follows:
- (a1) from 5% to 20% by weight the total composition;
- (a2) from 6% to 19% by weight the total composition;
- (a3) from 7% to 18% by weight the total composition;
- (a4) from 8% to 17% by weight the total composition;
- (a5) from 8% to 16% by weight the total composition;
- (a6) from 8% to 15% by weight the total composition;
- (a7) from 8% to 14% by weight the total composition;
- (a8) from 8% to 13% by weight the total composition;
- (a9) from 9% to 14% by weight the total composition;
- (a10) from 10% to 14% by weight the total composition;
- (a11) from 9% to 13% by weight the total composition;
- (a12) from 10% to 12% by weight the total composition;
- (a13) from 10% to 11% by weight the total composition.
- With respect to ingredient (c) noted above for example, the amount of sunflower lecithin that may be included in the final composition is based on a percent by weight of the total weight of the final composition described herein. The composition may comprise ingredient (c) for example, in concentrations as follows:
- (c1) from 1% to 20% by weight the total composition;
- (c2) from 2% to 19% by weight the total composition;
- (c3) from 3% to 18% by weight the total composition;
- (c4) from 4% to 17% by weight the total composition;
- (c5) from 4% to 16% by weight the total composition;
- (c6) from 4% to 15% by weight the total composition;
- (c7) from 4% to 14% by weight the total composition;
- (c8) from 4% to 13% by weight the total composition;
- (c9) from 4% to 12% by weight the total composition;
- (c10) from 4% to 11% by weight the total composition;
- (c11) from 5% to 10% by weight the total composition;
- (c12) from 6% to 9% by weight the total composition;
- (c13) from 6% to 8% by weight the total composition.
- With respect to ingredient (a) noted above for example, the L-glutathione reduced may comprise a purity before it is included in the composition in percentages as follows:
- (aa1) from 97% to 99.9% purity;
- (aa2) from 97.5% to 99.9% purity;
- (aa3) from 98% to 99.9% purity;
- (aa4) from 98.5% to 99.9% purity;
- (aa5) from 99% to 99.9% purity;
- (aa6) from 99.1% to 99.9% purity;
- (aa7) from 99.2% to 99.9% purity;
- (aa8) from 99.3% to 99.9% purity;
- (aa9) from 99.4% to 99.9% purity;
- (aa10) from 99.5% to 99.9% purity;
- (aa11) from 99.6% to 99.9% purity;
- (aa12) from 99.7% to 99.9% purity;
- (aa13) from 99.8% to 99.9% purity.
- The foregoing percentages, concentrations, and ratios are presented by example only and are not intended to be exhaustive or to limit the disclosure to the precise percentages, concentrations, and ratios disclosed. It should be appreciated that each value that falls within a disclosed range is disclosed as if it were individually disclosed as set forth herein. For example, a range indicating a weight percent from about 8% to about 14% additionally includes ranges beginning or ending with all values within that range, including for example a range beginning at 8.1%, 8.2%, 8.3%, and so forth.
- Also, according to one or more non-limiting embodiments of the disclosure, any of the concentrations for ingredients (a) or (c), for example, as listed above, may indicate the concentration for any of ingredients (b) and (d) thru (h), as listed above. For example, an embodiment of the disclosure may comprise, for example, (a7) from 8% to 14% by weigh the total composition of L-glutathione reduced, and equal parts by weight of lemon essential oil and peppermint essential oil. For example, the composition may comprise all, or any combination of but not all, of the ingredients (a) thru (h).
- The foregoing description has been presented for the purposes of illustration and description. It is not intended to be exhaustive or to limit the disclosure to the precise form disclosed. Many modifications and variations are possible in light of the above teaching. Further, it should be noted that any or all the aforementioned alternate implementations might be used in any combination desired to form additional hybrid implementations of the disclosure.
- Further, although specific implementations of the disclosure have been described and illustrated, the disclosure is not to be limited to the specific forms or arrangements of parts so described and illustrated. The scope of the disclosure is to be defined by the claims appended hereto, any future claims submitted here and in different applications, and their equivalents.
Claims (28)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16/368,057 US20190240281A1 (en) | 2017-02-17 | 2019-03-28 | Oral anaerobic glutathione supplement in liposome suspension |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762460725P | 2017-02-17 | 2017-02-17 | |
US15/955,608 US10272130B1 (en) | 2017-02-17 | 2018-04-17 | Oral anaerobic glutathione supplement in liposome suspension |
US16/368,057 US20190240281A1 (en) | 2017-02-17 | 2019-03-28 | Oral anaerobic glutathione supplement in liposome suspension |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/955,608 Continuation US10272130B1 (en) | 2017-02-17 | 2018-04-17 | Oral anaerobic glutathione supplement in liposome suspension |
Publications (1)
Publication Number | Publication Date |
---|---|
US20190240281A1 true US20190240281A1 (en) | 2019-08-08 |
Family
ID=66248071
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/955,608 Active US10272130B1 (en) | 2017-02-17 | 2018-04-17 | Oral anaerobic glutathione supplement in liposome suspension |
US16/368,057 Abandoned US20190240281A1 (en) | 2017-02-17 | 2019-03-28 | Oral anaerobic glutathione supplement in liposome suspension |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US15/955,608 Active US10272130B1 (en) | 2017-02-17 | 2018-04-17 | Oral anaerobic glutathione supplement in liposome suspension |
Country Status (1)
Country | Link |
---|---|
US (2) | US10272130B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021222835A1 (en) * | 2020-04-30 | 2021-11-04 | Purser Danny C | Compositions and methods comprising stable reduced glutathione |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10272130B1 (en) * | 2017-02-17 | 2019-04-30 | Stephen N. Pitcher | Oral anaerobic glutathione supplement in liposome suspension |
US20240009265A1 (en) * | 2020-04-30 | 2024-01-11 | Blue Sky Innovation, Llc | Methods of treatment comprising stable reduced glutathione |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10272130B1 (en) * | 2017-02-17 | 2019-04-30 | Stephen N. Pitcher | Oral anaerobic glutathione supplement in liposome suspension |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2408399A1 (en) * | 2000-05-09 | 2001-11-15 | Nitromed, Inc. | Infrared thermography and methods of use |
US6835811B1 (en) * | 2001-03-13 | 2004-12-28 | Kromar Medical Corporation | Extended storage of reduced glutathione solutions |
US20140023696A1 (en) * | 2012-07-20 | 2014-01-23 | Frederick Timothy Guilford | Treatment for idiopathic pulmonary fibrosis |
WO2014176224A1 (en) * | 2013-04-24 | 2014-10-30 | Somahlution, Llc | Organ and tissue preservation solutions having increased oxygen-content, stability and shelf life |
-
2018
- 2018-04-17 US US15/955,608 patent/US10272130B1/en active Active
-
2019
- 2019-03-28 US US16/368,057 patent/US20190240281A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10272130B1 (en) * | 2017-02-17 | 2019-04-30 | Stephen N. Pitcher | Oral anaerobic glutathione supplement in liposome suspension |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021222835A1 (en) * | 2020-04-30 | 2021-11-04 | Purser Danny C | Compositions and methods comprising stable reduced glutathione |
Also Published As
Publication number | Publication date |
---|---|
US10272130B1 (en) | 2019-04-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20190240281A1 (en) | Oral anaerobic glutathione supplement in liposome suspension | |
EP0969744B1 (en) | Nutritional composition for improvements in cell energetics | |
JP2011144186A (en) | Composition comprising nadh/nadph | |
TWI245628B (en) | Stabilized composition of reduced coenzyme Q10 aqueous solution | |
ZA200600203B (en) | Multivitamin syrup for children or young adults | |
ITRM980636A1 (en) | USE OF CARNITINE AND RESVERATROL TO PRODUCE A COMPOSITION FOR THE PREVENTION OR THERAPEUTIC TREATMENT OF BRAIN ALTERATIONS CAUSED BY AGING AND NEUROTOXIC DRUGS. | |
EP1880000B1 (en) | Yeast preparations with improved antioxidant properties and uses thereof | |
Kurowska et al. | Relative bioavailability and antioxidant potential of two coenzyme Q10 preparations | |
US20080171032A1 (en) | Dietary supplement composition and method of use for the treatment and prevention of oxidative stress | |
WO2007115131A2 (en) | Liposomal reduced glutathione and 1-arginine, including other ingredient(s) | |
US20200338153A1 (en) | Anaerobic antioxidant composition | |
EP0655244B1 (en) | Amino acid composition for the treatment of infections | |
JP6794490B2 (en) | Anaerobic antioxidant composition | |
CA3041914C (en) | Anaerobic antioxidant composition | |
EP3733197A1 (en) | Anaerobic antioxidant composition | |
EP2675463B1 (en) | Aqueous ionic solution containing seawater and at least one compound that is originally immiscible with seawater | |
CA2285490C (en) | Composition for improvement of cellular nutrition and mitochondrial energetics | |
AU2023203576A1 (en) | Anaerobic antioxidant composition | |
EP3419588A1 (en) | Composition for topical use based on a carnosine-magnesium complex | |
JP5984956B2 (en) | Composition based on ubidecarenone | |
JP2003335665A (en) | Composition for regulating in vivo vitamin c level | |
JP7407515B2 (en) | Composition for internal use | |
EP1317239A1 (en) | Synergetic combinations based on plants for treating hair loss | |
US20240100114A1 (en) | Composition for hydration and reducing the effects of acohol | |
EP3936120A1 (en) | Hydrogen-generating compositions and kits |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STPP | Information on status: patent application and granting procedure in general |
Free format text: NON FINAL ACTION MAILED |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCV | Information on status: appeal procedure |
Free format text: NOTICE OF APPEAL FILED |
|
STCV | Information on status: appeal procedure |
Free format text: NOTICE OF APPEAL FILED |
|
STCV | Information on status: appeal procedure |
Free format text: APPEAL BRIEF (OR SUPPLEMENTAL BRIEF) ENTERED AND FORWARDED TO EXAMINER |
|
AS | Assignment |
Owner name: BLUE SKY INNOVATION, LLC, UTAH Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:PITCHER, STEPHEN N.;PURSER, DANNY C.;SIGNING DATES FROM 20211018 TO 20211020;REEL/FRAME:058143/0398 |
|
STCV | Information on status: appeal procedure |
Free format text: EXAMINER'S ANSWER TO APPEAL BRIEF MAILED |
|
STCV | Information on status: appeal procedure |
Free format text: ON APPEAL -- AWAITING DECISION BY THE BOARD OF APPEALS |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: DOCKETED NEW CASE - READY FOR EXAMINATION |
|
STPP | Information on status: patent application and granting procedure in general |
Free format text: FINAL REJECTION MAILED |
|
STCV | Information on status: appeal procedure |
Free format text: NOTICE OF APPEAL FILED |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |